IRLAB Therapeutics AB is a Sweden-based research and development company. It focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinsonâ€™s disease. The Company possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The Company operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinsonâ€™s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).

Employees

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company

Market Cap	205M 21.21M 18.56M 17.11M 15.83M 30.05M 2.02B 30.55M 80.33M 994M 79.63M 77.91M 3.44B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	205M 21.21M 18.56M 17.11M 15.83M 30.05M 2.02B 30.55M 80.33M 994M 79.63M 77.91M 3.44B	EV / Sales 2026 *	2.01x	EV / Sales 2027 *	1.45x
Free-Float	38.17%	Yield 2026 *	-	Yield 2027 *	-

07-08	Irlab board member James Gamgort buys shares for just under SEK 0.3m	FW
06-30	IRLAB Therapeutics AB Approves Election of Janne Backman as Vice Chairperson of the Board of Directors	CI
06-30	IRLAB Therapeutics Rights Issue Raises About SEK 68 Mln	RE
06-30	Irlab Therapeutics Raises SEK76.5 Million from Oversubscribed Rights Offering	MT
06-30	Irlab rights issue oversubscribed	FW
06-16	IRLAB Therapeutics Presents Integrated Analysis of Mesdopetam Data at International Conference and Confirms Robust Efficacy Results in The Phase II Studies	CI
06-16	Irlab highlights positive data for mesdopetam	FW
06-08	Irlab shares trade ex-rights on Nasdaq Stockholm following rights issue	FW
06-05	IRLAB Therapeutics AB Announces Board Elections, Effective June 5, 2026	CI
06-05	Irlab rights issue now 91 percent secured	FW
05-06	IRLAB Q1 operating result swings to profit of SEK 10.7 mln	RE
05-06	Irlab reports growth in revenue and operating profit	FW
05-06	IRLAB Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

11-04	Redeye Lowers Fair Value for Irlab to 12 Kronor (from 17)	FW
13/05/24	Irlab rises almost double-digit - Redeye raises motivated value	FW
13/05/24	Redeye raises motivated value for Irlab to SEK 40 (35)	FW
12/02/24	Edison lowers motivated value for Irlab	FW
30/12/23	Bonesupport winner of the year and Viaplay loser of the year on Nasdaq Stockholm 2023	FW

06-30	Report from the Annual General Meeting 2026 of IRLAB Therapeutics AB	AQ
06-16	IRLAB Presents Integrated Analysis of Mesdopetam Data at International Conference - Confirms Robust Efficacy Results in the Phase II Studies	AQ
06-16	IRLAB presents integrated analysis of mesdopetam data at international conference – confirms robust efficacy results in the Phase II studies	AQ
06-05	IRLAB publishes information document in connection with the rights issue and announces that additional subscription undertakings have been received	AQ
06-05	Report from the Extraordinary General Meeting of IRLAB Therapeutics AB	AQ

Manager	Title	Age	Since
Clas Sonesson CTO	Chief Tech/Sci/R&D Officer	65	01/01/2016
Susanna Waters PRN	Corporate Officer/Principal	60	01/01/2013
Kristina Torfgård CEO	Chief Executive Officer	63	01/08/2024

IRLAB Therapeutics AB (publ) Stock Nasdaq Stockholm

Stocks

SE0012675361

Pharmaceuticals

Valuation: IRLAB Therapeutics AB (publ)

Latest news : IRLAB Therapeutics AB (publ)

Last Transcript: IRLAB Therapeutics AB (publ)

Analysts' recommendations: IRLAB Therapeutics AB (publ)

Press Releases: IRLAB Therapeutics AB (publ)

News in other languages: IRLAB Therapeutics AB (publ)

Quotes and Performance

Managers and Directors: IRLAB Therapeutics AB (publ)

Other Pharmaceuticals

Financials

Company Profile

Director	Title	Age	Since
Rein Piir BRD	Director/Board Member	68	01/01/2016
Gunnar Olof Olsson CHM	Chairman	73	07/05/2020
Carola Elisabet Lemne CHM	Chairman	68	20/02/2023

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IRLAB THERAPEUTICS AB (PUBL)	-3.04%	-3.97%	-	-	21.21M
ELI LILLY AND COMPANY	+0.09%	+0.25%	+54.65%	+169.19%	1,085B
JOHNSON & JOHNSON	-1.63%	-1.50%	+65.79%	+62.70%	624B
ABBVIE INC.	-1.12%	-4.27%	+31.10%	+84.44%	442B
ROCHE HOLDING AG	+0.18%	-1.76%	+29.04%	+26.51%	332B
ASTRAZENECA PLC	-6.22%	-8.14%	+28.87%	+32.09%	277B
NOVARTIS AG	-1.27%	-2.91%	+27.42%	+46.39%	282B
NOVO NORDISK A/S	-0.93%	-3.57%	-27.74%	-40.38%	217B
AMGEN INC.	-1.19%	-2.81%	+22.63%	+66.30%	196B
GILEAD SCIENCES, INC.	-0.72%	+2.72%	+19.07%	+81.19%	167B
Average	-1.46%	-1.86%	+27.87%	+58.71%	402.44B
Weighted average by Cap.	-0.88%	-1.06%	+38.95%	+85.21%

	2026 *	2027 *
Net sales	102M 10.56M 9.24M 8.52M 7.88M 14.96M 1.01B 15.21M 39.98M 495M 39.64M 38.78M 1.71B	142M 14.68M 12.84M 11.84M 10.96M 20.79M 1.4B 21.14M 55.59M 688M 55.1M 53.91M 2.38B
Net income	-32.6M -3.37M -2.95M -2.72M -2.52M -4.78M -322M -4.86M -12.78M -158M -12.67M -12.39M -548M	33.3M 3.45M 3.02M 2.78M 2.57M 4.88M 329M 4.96M 13.05M 162M 12.94M 12.66M 560M
Net Debt	-	-